Résumé
In recent years, the bloodstream infection rate of Gram-negative bacilli has continued to increase. Among them, drug-resistant bacteria have a higher mortality rate and longer hospital stay, especially the bloodstream infection of carbapenem-resistant Acinetobacter baumannii (CRAB). Polymyxin began to be used clinically in the 1950s and has antibacterial activity against multidrug resistant and poly drug-resistant Gram-negative bacilli. It can also be used as an effective permeation agent for the cell envelope of Gram-negative bacilli. Polymyxin is reserved for microbiologically clear drug-resistant Gram-negative bacilli infections. The World Health Organization classifies polymyxin as an antimicrobial drug with clinical significance for human infections and can be used to treat drug-resistant Acinetobacter baumannii infection. This article reviews the clinical treatment of polymyxin in bloodstream infections of drug-resistant Acinetobacter baumannii, to provide reference for clinical medication.